This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Theragenics Reports Fourth Quarter And Year-End 2012 Results

Theragenics Corporation ® (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the fourth quarter and year ended December 31, 2012.

Consolidated Results

  • Consolidated revenue
    • $19.1 million in the fourth quarter, down 4% from 2011
    • $82.6 million for the year, flat compared with 2011
  • Earnings per share
    • Loss of $0.01 in fourth quarter compared to earnings of $0.01 in 2011
    • Earnings of $0.07 for 2012 compared to $0.09 in 2011
  • Cash flow from operations of $13.2 million in 2012 compared to $6.1 million in 2011
  • Adjusted EBITDA
    • $2.0 million in fourth quarter compared to $2.6 million in 2011
    • $12.6 million in 2012 compared to $13.5 million in 2011
  • At December 31, 2012 cash, cash equivalents and marketable securities were $34.9 million and credit facility borrowings were $22.0 million, resulting in a net positive position of $12.9 million

Segment Results

  • Revenue
    • Surgical products
      • $14.3 million in the fourth quarter, flat compared to 2011
      • $59.9 million for the year, up 1% from 2011
    • Brachytherapy
      • $5.1 million for the quarter, down 12% from 2011
      • $23.6 million for the year, down 2% from 2011
        • Incremental revenue in the Brachytherapy segment from acquired Core customers was $793,000 in the fourth quarter and $3.6 million for the year
      • Operating income
        • Surgical products
          • Loss from operations of $334,000 in the fourth quarter compared to a loss of $480,000 in 2011
          • Operating income of $696,000 for the year compared to $607,000 in 2011
        • Brachytherapy
          • Operating income of $89,000 in fourth quarter, compared to $1.1 million in 2011
          • Operating income of $3.1 million for the year compared to $4.9 million in 2011

Comments

“The momentum from our first half of 2012 was erased in the second half of 2012,” stated M. Christine Jacobs, Chairman and CEO. “We faced sector-wide anemic growth and continuing customer uncertainty resulting in soft demand across all of our business units. Every strategic accomplishment of 2012 was masked by soft demand and the high fixed cost components of our operations.”

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs